Company intelligence / Profile preview

Rhenium Oncotest

Modi'in-Maccabim-Reut, Israeloncotest.co.il ↗

Ownership: Private
Development stage: Commercial

Overview

Rhenium Oncotest has been a pioneer in providing advanced cancer diagnostic and precision medicine services in Israel since 1998. The company offers comprehensive genomic testing, such as the Guardant360® liquid biopsy, which analyzes over 70 clinically relevant genes to guide treatment decisions for advanced-stage cancer patients. These services are fully commercialized and widely used by oncology professionals across Israel.

Therapeutic areas: Oncology
Modalities: Diagnostic testGenomic testing (liquid biopsy)
Industry: Molecular Diagnostics

Partnerships

Guardant Health (for Guardant360® assay)

Beyond the preview

Go deeper on Rhenium Oncotest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhenium Oncotest.

Explore the full profile